Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer

Abstract

The global phase 3 DESTINY-Breast03 study (ClinicalTrials.gov; NCT03529110) showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan (T-DXd) over trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane. Here, we report a subgroup analysis of Asian patients enrolled in DESTINY-Breast03. In total, 309 patients (149 in the T-DXd arm and 160 in the T-DM1 arm) from Asian countries and regions were randomized. At data cutoff (July 25, 2022), the median duration of follow-up in the Asian subpopulation was 29.0 months with T-DXd and 26.0 months with T-DM1. The PFS (determined by blinded independent central review) hazard ratio was 0.30 (95% confidence interval 0.22-0.41) favoring T-DXd over T-DM1 (median PFS 25.1 vs. 5.4 months). Median OS was not reached in the T-DXd arm and was 37.7 months in the T-DM1 arm. The median treatment duration was 15.4 months with T-DXd and 5.5 months with T-DM1. The incidence of grade ≥3 drug-related treatment-emergent adverse events was similar between both treatment arms (49.0% vs. 46.5%) and was consistent with the overall DESTINY-Breast03 population. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.9% of patients treated with T-DXd and 2.5% treated with T-DM1, with a higher incidence in Japanese patients; none of these were grade ≥4 events. These efficacy and safety data reinforce the favorable benefit-risk profile of T-DXd in HER2-positive mBC, including in the Asian subgroup.

Keywords: East Asia; ErbB‐2 receptor; breast cancer; trastuzumab deruxtecan; trastuzumab emtansine.

FIGURE 1

Kaplan–Meier analysis of progression‐free survival, assessed by blinded independent central review, among Asian patients enrolled in the DESTINY‐Breast03 study. CI, confidence interval; HR, hazard ratio; NE, not estimable; T‐DM1, trastuzumab emtansine; T‐DXd, trastuzumab deruxtecan.

FIGURE 2

Progression‐free survival in prespecified subgroups. ^aLines of previous therapy did not include endocrine therapy. CI, confidence interval; NE, not estimable; PFS, progression‐free survival; T‐DM1, trastuzumab emtansine; T‐DXd, trastuzumab deruxtecan.

FIGURE 3

Kaplan–Meier analysis of overall survival among Asian patients enrolled in the DESTINY‐Breast03 study. CI, confidence interval; HR, hazard ratio; NE, not estimable; T‐DM1, trastuzumab emtansine; T‐DXd, trastuzumab deruxtecan.